NEW YORK, NY —
Physicians from the department of neurosurgery at Lenox Hill Hospital are participating in a clinical research study to test the efficacy and safety of a combination of disulfiram and copper called CX-02, as an investigational treatment for one of the most aggressive forms of brain cancer – glioblastoma multiforme (GBM).
The research is sponsored by Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing proprietary pharmaceuticals that improve the treatment of cancers and other life-threatening disorders.
The study entitled, "A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma," is being led by John Boockvar, MD, the hospital's vice chair, neurosurgery and director of Lenox Hill's Brain Tumor Center.
"Glioblastoma multiforme is an aggressive malignant brain tumor in great need of new and more effective treatments," said Dr. Boockvar. "Evidence found in pre-clinical studies has indicated that the combination of disulfiram and copper, CX-02, has cancer cell-killing effects against glioblastoma and enhances the effectiveness of temozolomide, a modestly effective chemotherapy medication for glioblastoma. We are excited to study this potential treatment of recurrent glioblastoma."
Dr. Boockvar also commented, "Medulloblastoma is the most common primary malignant brain tumor in children. Based on promising early results, the Feinstein Institute for Medical Research, Northwell Health's principal medical research facility, is conducting pre-clinical laboratory evaluation of the effect of the combination of disulfiram and copper in laboratory and animal studies of medulloblastoma. Presentation of early results is expected later this year."
Stephen Marcus, M.D., chief executive officer of Cantex Pharmaceuticals, Inc., said, "Collaborations between centers of excellence, such as Lenox Hill Hospital and the Feinstein Institute, are critical to the successful development of novel effective treatments of cancer and other life-threatening illnesses. We are very pleased to have this opportunity to work with Lenox Hill's outstanding team of physicians and scientists in the clinical development of CX-02, our proprietary combination of disulfiram and copper."
The multi-centered study will evaluate the efficacy, safety, and tolerability of CX-02 in approximately 20 patients with recurrent glioblastoma. The endpoints of the study will include response rate as indicated by magnetic resonance imaging (MRI) findings, progression-free survival at six months, and overall survival.
For more information about this research study at Lenox Hill Hospital, contact Tamika Wong, MPH at 212-434-8436.
# # #
About Lenox Hill Hospital
Lenox Hill Hospital, a member of Northwell Health, is a 652-bed, fully accredited, acute care hospital located on Manhattan's Upper East Side with a national reputation for outstanding patient care and innovative medical and surgical treatments. US News & World Report has ranked the hospital among the nation's top 50 in Cardiology and Heart Surgery and among the top 10 hospitals in the state of New York with a total of 11 "high performing" designations for its clinical performance in Cancer, Diabetes & Endocrinology, Ear, Nose & Throat, Gastroenterology & GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology & Neurosurgery, Orthopedics, Pulmonology and Urology. For more information, go to www.lenoxhillhospital.org
About Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancers and other life-threatening disorders. Cantex's CX-02 is a proprietary combination of disulfiram and copper. CX-02 is currently in a Phase II clinical trial for recurrent glioblastoma. An additional clinical trial evaluating CX-02 in metastatic prostate cancer is also in progress. Cantex's other clinical stage product, CX-01, is currently in a randomized Phase IIB trial of CX-01 in newly diagnosed acute myeloid leukemia as well as a Phase II trial in patients with refractory myelodysplastic syndrome. For more information, please visit www.cantex.com.